Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio
12 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio" is generating significant coverage in the Business category, with 15 articles from 12 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Crain's Chicago Business, Reuters, Yahoo Finance and WSJ. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 17d ago.
Quick answers
Why is "Lilly reports third-quarter 2026 financial results, raises full-year guidance an" trending?
Because 12 independent news sources published 15 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (21)
- As Skyrizi and Rinvoq dominate AbbVie's Q3, analysts ask what's next Fierce Pharma · 17d ago
- LLY, ABBV Stocks Hit All-Time High TradingView · 17d ago
- Here's What Key Metrics Tell Us About AbbVie (ABBV) Q3 Earnings Yahoo Finance · 17d ago
- AbbVie's Profit Doubles As Immunology King Beats Again Investor's Business Daily · 17d ago
- AbbVie (ABBV) Set to Report Q3 Earnings Amid Dividend Sustainabi GuruFocus · 17d ago
- AbbVie beats estimates but stock dips Yahoo Finance · 17d ago
- AbbVie’s earnings double as drugmaker eyes a move into obesity treatments Crain's Chicago Business · 17d ago
- AbbVie lifts annual profit forecast as immunology drugs continue to fuel growth Reuters · 17d ago
- AbbVie: Q3 Earnings Snapshot Yahoo Finance · 17d ago
- AbbVie Revenue Rises on Strength in Immunology, Neuroscience WSJ · 17d ago
- AbbVie Reports Third-Quarter 2026 Financial Results AbbVie News Center · 17d ago
- Starbucks Reports Q4 and Full Fiscal Year 2026 Results Starbucks Investor Relations · 18d ago
- Eli Lilly hikes sales outlook, as CEO says there's room for 'dramatic' obesity market expansion CNBC · 18d ago
- Eli Lilly’s Medicare Pilot Helps Fuel A $5 Billion Raise Finimize · 18d ago
- Eli Lilly Stock (LLY) Soars as Financial Results Crush Wall Street Estimates TipRanks · 18d ago
- Lilly’s obesity drug strength fuels record rally, Wall Street optimism 95.7 KELO-FM · 18d ago
- Eli Lilly stock jumps as drugmaker raises outlook on booming sales of diabetes and obesity treatments Yahoo Finance · 18d ago
- Eli Lilly profits surge on demand for weight-loss drugs Financial Times · 18d ago
- Ahead of Eli Lilly Earnings, Here's What Barchart Data Says Comes Next for LLY Stock Yahoo Finance · 18d ago
- Eli Lilly raised its outlook a third time in Q3 2026 earnings Quartz · 18d ago
- Lilly: Q3 Earnings Snapshot Yahoo Finance · 18d ago
Topics
Related trends
Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data
Foghorn Therapeutics cuts 40% of staff after Eli Lilly ends a cancer collaboration due to poor data.
GLP-1 makers Novo, Eli Lilly sued over sudden loss of vision in patients
Major drugmakers Novo Nordisk and Eli Lilly face numerous lawsuits alleging popular GLP-1 medications cause sudden vision loss.
Wegovy-maker Novo faces calls to map out strategy beyond weight-loss drugs
Novo Nordisk shares slide despite aggressive obesity targets as investors demand a broader long-term strategy.
Eli Lilly Stock Jumps on Monster Earnings as Finance Chief Eyes Next Growth Engine
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Eli Lilly CFO On Acquisition Spree: 'We Are Taking Bets' On Future Revenue
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
Eli Lilly stock reaches an all-time high amid surging GLP-1 sales and a heightened price target.